Keywords
Inibidores do SGLT2
Diabetes Mellitus
How to Cite
Abstract
This article addresses the use of SGLT2 inhibitors in the treatment of heart failure. Objective: Patients with IC and diabetes mellitus (DM) had a reduction in hospitalizations for IC after using SGLT2, improved glycemic control and, consequently, improved health status. However, the biological mechanisms of SGLT2 in treating left ventricular ejection fraction are uncertain. Methods: Based on bibliographic research of articles with the descriptors "SGLT2" and "Heart Failure". Data were obtained without language limitations from MEDLINE via PubMed, Lilacs and SciELO. Results: Studies such as DECLARE-TIMI 5814, EMPEROR-REDUCED, DAPA-HF, CANVAS, EMPEROR-PRESERVED and DELIVER were found, whereby SGLT2 proved to be effective in reducing hospitalizations and cardiovascular deaths from HF, whether patients have or not from DM. Concomitantly, there was an improvement in symptoms, cardiac efficiency and cardiac subsidy. Conclusions: Studies on the mechanisms of SGLT2 are still needed, however, benefits are shown for HF associated or not with DM, providing a reduction in hospitalizations due to HF and cardiovascular mortality, an increase in quality of life and a better prognosis, with safety, good tolerance and low rate of adverse effects.
References
ANKER, Stefan D. et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine, 27 ago. 2021. Disponível em: https://doi.org/10.1056/nejmoa2107038.
BHATT, Deepak L.; VERMA, Subodh; BRAUNWALD, Eugene. The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure. Cell Metabolism, v. 30, n. 5, p. 847-849, nov. 2019. Disponível em: https://doi.org/10.1016/j.cmet.2019.10.008.
BUTLER, Javed et al. Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta‐analysis. ESC Heart Failure, v. 7, n. 6, p. 3298-3309, dez. 2020. Disponível em: https://doi.org/10.1002/ehf2.13169.
CHERNEY, David Z. I. et al. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial. The Lancet Diabetes & Endocrinology, v. 8, n. 7, p. 582-593, jul. 2020. Disponível em: https://doi.org/10.1016/s2213-8587(20)30162-5.
DAMMAN, Kevin et al. Randomized, double‐blind, placebo‐controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA‐RESPONSE‐AHF). European Journal of Heart Failure, v. 22, n. 4, p. 713-722, 7 jan. 2020. Disponível em: https://doi.org/10.1002/ejhf.1713.
LYTVYN, Yuliya et al. Response by Lytvyn et al to Letter Regarding Article, “Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials”. Circulation, v. 137, n. 18, p. 1984-1985, maio 2018. Disponível em: https://doi.org/10.1161/circulationaha.117.033238.
MARX, Nikolaus; MÜLLER-WIELAND, Dirk. SGLT2 inhibitors in heart failure and type 2 diabetes: from efficacy in trials towards effectiveness in the real world. European Heart Journal, 8 jun. 2023. Disponível em: https://doi.org/10.1093/eurheartj/ehad282.
MCMURRAY, John J. V. et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, v. 381, n. 21, p. 1995-2008, 21 nov. 2019. Disponível em: https://doi.org/10.1056/nejmoa1911303.
METRA, Marco et al. Effects of Serelaxin in Patients with Acute Heart Failure. New England Journal of Medicine, v. 381, n. 8, p. 716-726, 22 ago. 2019. Disponível em: https://doi.org/10.1056/nejmoa1801291.
MURPHY, Sean P.; IBRAHIM, Nasrien E.; JANUZZI, James L. Heart Failure With Reduced Ejection Fraction. JAMA, v. 324, n. 5, p. 488, 4 ago. 2020. Disponível em: https://doi.org/10.1001/jama.2020.10262.
NEAL, Bruce et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. New England Journal of Medicine, v. 377, n. 7, p. 644-657, 17 ago. 2017. Disponível em: https://doi.org/10.1056/nejmoa1611925.
PACKER, Milton et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New England Journal of Medicine, v. 383, n. 15, p. 1413-1424, 8 out. 2020. Disponível em: https://doi.org/10.1056/nejmoa2022190.
SANTOS-GALLEGO, Carlos G. et al. Randomized Trial of Empagliflozin in Non-Diabetic Patients with Heart Failure and Reduced Ejection Fraction. Journal of the American College of Cardiology, nov. 2020. Disponível em: https://doi.org/10.1016/j.jacc.2020.11.008.
SOLOMON, Scott D. et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. New England Journal of Medicine, 27 ago. 2022. Disponível em: https://doi.org/10.1056/nejmoa2206286.
SPERTUS, John A. et al. The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. Nature Medicine, v. 28, n. 4, p. 809-813, 28 fev. 2022. Disponível em: https://doi.org/10.1038/s41591-022-01703-8.
VERMA, Subodh; MCMURRAY, John J. V. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia, v. 61, n. 10, p. 2108-2117, 22 ago. 2018. Disponível em: https://doi.org/10.1007/s00125-018-4670-7.
WIVIOTT, Stephen D. et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, v. 380, n. 4, p. 347-357, 24 jan. 2019. Disponível em: https://doi.org/10.1056/nejmoa1812389.
ZINMAN, Bernard et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine, v. 373, n. 22, p. 2117-2128, 26 nov. 2015. Disponível em: https://doi.org/10.1056/nejmoa1504720.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Letícia Grolla Matos, Alana Neves da Costa , Bianca Teixeira Souza , Eduarda Negrini de Souza , Fernanda Dardengo Gava , Sthephany Pereira Peixoto , Yasmin Oliveira Gil de Almeida , Wilson da Silva Gonçalves Junior